Summary An epthelial cell surface antigen is described which is defined by monoclonal antibody HEA125 (IgGI) 
Since the advent of hybridoma technology numerous efforts have been made to generate monoclonal antibodies with specificity for plasma membrane antigens of selelcted epithelial cell types and their tumours (Koprowski et al., 1972; Metzgar et al., 1982; Schmiegel et al., 1985; Togashi et al., 1984; Colcher et al., 1981; Stacker et al., 1985; Bernal et al., 1984; Reeve et al., 1985; Bast et al., 1981; Ueda et al., 1981; Masuko et al., 1984; Frankel et al., 1982) . Most monoclonal antibodies (MAbs) to epithelial cell surface components described so far recognize differentiation antigens that i) are not specific for the malignant phenotype, that ii) bind to the tumour cells of an individual carcinoma with considerable heterogeneity, and that iii) are undetectable in a subset of tumours of a given origin (reviewed in Edwards, 1985) .
In contrast to antigens with a restricted and heterogeneous expression among human epithelial tumours, surface antigens with wide distribution and homogeneous expression in these neoplasms would be helpful in the diagnosis of anaplastic carcinomas in immunocytochemistry and immunohistochemistry provided the antigens are expressed in a strictly epithelium-specific manner. Antibodies to such antigens would be suitable tools for staining and targeting of viable carcinoma cells in vitro and in vivo. In the present investigation we report on a monoclonal antibody that reacts with a cell surface antigen of Mr 34,000 present on all carcinoma cell lines tested, however, not on various cell lines and normal cells of non-epithelial origin. Biochemical characteristics of the antigen are described and the presence of soluble antigen in sera of cancer patients is examined. An immunohistological survey of human tissues demonstrates the strong and homogeneous expression of the antigen in most normal epithelial cell types and in carcinomas. An epithelium-specific pattern of expression of the M, 34, 000 antigen is also found in tissues.
Materials and methods
Cell lines and tissues Cell lines of various tissue origins as indicated in Table I were provided by the following institutions. From Suspension cell lines were grown in RPMI 1640 medium completed with 10% heat-inactivated foetal calf serum, 2mM L-glutamine, 1 mM pyruvate, penicillin-streptomycin 100Uml-' (all components from Gibco, Karlsruhe, FRG). Adherent cell lines were cultivated in complete RPMI 1640 supplemented with 50 puM 2-mercaptoethanol, 1% (v/v) nonessential amino acids (Seromed, Berlin, FRG) and 4IUI-human insulin (Novo, Mainz, FRG) . Cell lines were mechanically harvested from monolayer cell cultures after treatment with 0.25% EDTA, washed twice in RPMI 1640 and used for cell binding assays and immunizations. P3X63Ag8.653 murine myeloma cells (Kearney et al., 1979) were maintained in complete RPMI 1640 medium.
Specimens of normal and neoplastic tissues were obtained from surgical material and snap-frozen in liquid nitrogen within two hours after removal.
Immunization and hybridoma production Female BALB/c mice were immunized by i.p. injection of -2 x 107 viable HT-29 cells. The mice were boosted four times at four-week intervals with 1-2 x 107 HT-29 cells i.p., the last injection 3 days prior to the fusion experiment.
Fusions were performed essentially as described by Galfre et al. (1977) . Splenocytes from immune spleens and Ag8.653 myeloma cells were mixed at a cell ratio of 5: 1 and fused in 1.5ml of 45% polyethylene glycol 4000 (Merck, Darmstadt, FRG) Radiobinding assays HEA 125 was purified from ascites fluid by DEAE Affi-Gel Blue (Biorad, Munic, FRG) chromatography (Bruck et al., 1982) . Radioiodination of MAb was performed by a slight modification of the chloramine-T method (Greenwood et al., 1963) Figure 1 illustrates the strong membrane staining of fixed ME-180 cervix carcinoma cells by HEA125. By contrast, no reaction was found with any of the non-carcinoma cell lines used, which were derived from melanoma, neuroblastoma, sarcoma and leukaemia/ lymphoma of the B, T and myelomonocytic lineage. Accordingly, no binding was found to normal lung fibroblasts, as it was the case for the cell types of normal peripheral blood.
.or: Figure 2) . Carcinomas of 10 different origins were all homogeneously stained in all tumour cells with the exception of squamous cell carcinomas, two of which were even unreactive (Table  II) . The tumour cells of anaplastic, diffusely infiltrating carcinomas, e.g., of the stomach (Figure 2e) or the mammary gland, were reliably detected. No reaction was found in sarcomas, lymphomas and neurogenic tumours. A more detailed analysis of the immunohistological binding pattern is be given elsewhere (Momburg et al., 1987) .
Antigen characterization After surface radioiodination of HT-29 cells, glycoprotein fractions were isolated, immunoprecipitated with MAb HEA125 and analysed by sodium dodecylsulfate gel electrophoresis. In the presence of 2-mercaptoethanol a strongly labelled band of -34kD was found (Figure 3 ). In addition, (Figures 3 & 5) . Under non-reducing conditions a major 39 kD band and a minor 43 kD band were obtained indicating that the antigen does not consist of disulfide-bonded subunits (Figure 4) . To further study the nature of the antigen, HEA125 precipitates from HT-29 lysate were treated with endoglycosidase F which cleaves off N-linked carbohydrate residues. After Endo F treatment, the strongly labelled 34kD band was shifted to 29 kD (Figure 5) (Figure 7) . Based on the condition that the molar ratio of Egp34 to bound 1251 -HEA 125 is 1.0, which is the minimal assumption, Egp34 was found to be expressed on the surface in a copy number as high as 1 x 106 per cell. The dissociation constant of HEA125 was determined as 2.2 x 10-9 M.
Absence of Egp34 from the serum Since several tumour-associated antigens, e.g. carcinoembryonic antigen, are detectable in sera or other body fluids of cancer patients in elevated amounts, we analysed sera of colorectal cancer patients for the presence of soluble Egp34.
We were not able to detect Egp34 in NP-40 lysates of HT-29 cells when HEA125 was used both as the catcher and detector antibody in a sandwich radioimmunoassay indicating that the Egp34 molecule carries only one HEA125 epitope. Therefore, in a solid phase RIA HEA125 was employed as the catcher and radiolabeled, purified rabbit antibodies to HT-29 cells as the detector (Table III) CNumber of tumour positive for HEA125/number of tumours tested. (Thompson et al., 1983) . In comparison to HEA125, 250-3.6 exhibited a less broad reactivity (Mulshine et al., 1983) , 39 and 42kD (Okabe et al., 1984) , 40kD (Varki et al., 1984) and again 40kD Lee et al., 1985) , another MAb raised to mammary carcinoma precipitates a 43 kD molecule (Edwards et al., 1986) . The reactivities of these antibodies with malignant cell lines and with normal and malignant tissues have been determined with varying accuracy. However, in addition to the slight differences in molecular weights, the data on cell line reactivity and immunohistochemistry clearly indicate that these MAbs recognize antigens different from Egp34 because they show a considerably more restricted tissue reactivity.
Undifferentiated large cell tumours often pose great problems to the pathologist. Carcinomas, large cell lymphomas, amelanotic melanomas, seminomas and sometimes even sarcomas may come into question. Therefore, a reliable marker with specificity for a particular lineage is desirable. In contrast to other antibodies that tend to become unreactive with decreasing degree of tumour differentiation (Edwards, 1985) , HEA125 allows the recognition of tumour cells of anaplastic, diffusely infiltrating carcinomas. Hence, HEA125 may represent a valuable tool for the distinction of carcinomas from tumours of other lineages. The strong surface expression of Egp34 allows the separation of carcinoma cells from stromal cells in cell sorting procedures. This could improve clonogenic tumour cell assays which are employed for anti-tumour drug sensitivity testing of individual tumours. Furthermore, an immunoscintigraphic detection of tumour masses is conceivable. Metastatic deposits of carcinomas in the liver seem to be suitable targets since the surrounding hepatic parenchyma should not bind the antibody. In a pilot study, 131I-labelled HEA125 is currently applied for the detection of liver metastases in colon cancer patients.
